CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Proleukin for In-transit Melanoma - Details

Project Number PC0051-000
Brand Name Proleukin
Generic Name Aldesleukin (IL-2)
Strength 22 million IU/vial
Tumour Type Skin and Melanoma
Indication In-transit Melanoma
Funding Request Administered intra-lesionally, for the treatment of in-transit metastasis from melanoma in patients who have failed or are not candidates for surgery or other treatments
Review Status Complete
Pre Noc Submission Yes
NOC Date N/A
Manufacturer Novartis Pharmaceuticals Canada Inc.
Sponsor Cancer Care Ontario Melanoma Disease Site Group
Submission Date January 30, 2015
Submission Deemed Complete February 6, 2015
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ February 23, 2015
Check-point meeting March 26, 2015
pERC Meeting May 21, 2015
Initial Recommendation Issued June 4, 2015
Feedback Deadline ‡ June 18, 2015
Final Recommendation Issued June 22, 2015
Notification to Implement Issued July 8, 2015
Therapeutic Area In-transit Melanoma
Recommendation Type Reimburse

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.